BioXcel Therapeutics, Inc. BTAI 深 沪
等待开盘 03-26 09:30:00 美东时间
1.4206
-0.009
-0.66%
华盛通- 最 高1.49
- 今 开1.45
- 成交量 27.23万股
- 最 低 1.4101
- 昨 收 1.43
- 总市值 3479.97万
- 52周最高 8.08
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.17
- 委 比 -88.01%
- 总股本 2449.65万
- 历史最高 1144.00
- 量 比 0.60
- 振 幅 5.59%
- 历史最低 1.36
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $17
Rodman & Renshaw analyst Michael King initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $17.
03-17 20:06
BioXcel Therapeutics Announces Registered Direct Equity Financing
Bioxcel Therapeutics ( ($BTAI) ) just unveiled an update. On March 10, 2026, Bi...
03-12 09:09
BioXcel Therapeutics Commences ~$8M Offering Of Common Stocks, Warants
BioXcel Therapeutics, Inc. (the "Company") (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a
03-11 02:37
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.
03-06 23:27
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $10 to $6.
03-06 00:36
BioXcel Therapeutics Stock Rallies Opioid Study Success
BioXcel Therapeutics' stock rises premarket after Phase 2 data show BXCL501 reduced opioid withdrawal symptoms and may rival Lucemyra.
03-05 21:53
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Impact BioMedical (AMEX:IBO) shares rose 70.2% to $0.7 during Thursday...
03-05 20:05
BRIEF-Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal
BRIEF-Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal March 5 (Reuters) - BioXcel Therapeutics Inc BTAI.O : BIOXCEL THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 TOPLINE RESULTS FROM COLUMBIA UNIVERSITY-LED ST
03-05 20:03
